Achillion Pharmaceuticals Shares Surge On Positive Data

Shares of Achillion Pharmaceuticals, Inc. ACHN are trending higher on Monday following updated interim results from a Phase 2 study of its ACH-3102 treatment.

The company reported that “one hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.”

Following the favorable announcement, shares of Achillion were up more than 14 percent Monday morning at $12.44.